Engineered Probiotic Targeting for In Situ Sulforaphane Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Naturally occurring gut bacteria and chemopreventive metabolites from cruciferous vegetables are inadequate for effectively preventing and mitigating colorectal cancer due to low bioavailability, poor host-absorption, and inability to localize to cancer sites, and microbial synthesis of anticancer compounds faces issues with undefined dosage and cellular metabolic state.

Innovation Solution

Engineering gut bacteria to optimize the conversion of glucosinolate from cruciferous plants into sulforaphane by reprogramming commensal microbes to target colorectal cancer cells, using myrosinase to enhance chemopreventive efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If naturally occurring gut bacteria are used to convert glucosinolate, then the system is simple and safe, but the catalytic turnover is inadequate to elicit anticancer effects

Engineering Contradiction:

Improveanticancer efficacyVSAvoidcatalytic turnover

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the catalytic parameters of gut bacteria by introducing enhanced myrosinase enzyme variants with higher specific activity and catalytic turnover rates. The engineered bacteria maintain safety while achieving sufficient sulforaphane production through optimized enzymatic parameters including improved kcat values and substrate affinity.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If chemopreventive metabolites are consumed from cruciferous vegetables, then the therapeutic approach is natural and safe, but the bioavailability is low and host-absorption is poor

Engineering Contradiction:

Improvetherapeutic safetyVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent uses engineered gut bacteria as living intermediaries that reside in the gastrointestinal tract and continuously convert dietary glucosinolates into bioactive sulforaphane. This mediator system overcomes poor absorption by producing the active compound in situ, ensuring high local concentrations where it is needed while maintaining the safety of natural cruciferous vegetable compounds.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of manufacture

If microbes are used to synthesize anticancer compounds, then the system is sustainable and cost-effective, but the dosage is undefined and depends on cell density

Engineering Contradiction:

ImprovesustainabilityVSAvoiddosage control

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent implements feedback control mechanisms where the engineered gut bacteria respond to local conditions in the gastrointestinal tract, adjusting their metabolic activity based on substrate availability and environmental cues. This self-regulating system ensures consistent therapeutic effect while maintaining sustainability, as the bacteria naturally modulate their compound production according to physiological conditions.

Inventive Principle:

Principle #23Feedback

4Ease of operation

If naturally occurring gut bacteria are used, then the system is simple to administer, but the bacteria cannot localize to colorectal cancer locations

Engineering Contradiction:

Improveadministration simplicityVSAvoidlocalization accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent confers location-specific functionality to the engineered gut bacteria by equipping them with targeting moieties that recognize and bind to markers on colorectal cancer cells. This allows the bacteria to maintain their ease of oral administration while achieving precise localization to tumor sites through differential expression of adhesion molecules and targeting proteins.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The engineered gut bacteria system provides a cost-effective and sustainable strategy to therapeutically mitigate and prevent colorectal cancer with minimal side effects, achieving significant tumor reduction and cancer cell inhibition in vitro and in vivo.

Implementation Method 1

The conversion of glucosinolate to sulforaphane requires hydrolysis by the myrosinase enzyme (EC3.2.3.1)

Methodology Applied

Scientific EffectHydrolysis: Hydrolysis

Implementation Method 2

the myrosinase enzyme (EC3.2.3.1)

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 3

the catalytic turnover which is inadequate to elicit anticancer effects

Methodology Applied

Scientific EffectCatalysis: Catalysis

Data Source

PatentUS12569523B2Engineered therapeutic probiotic system and method

Publication Date: 2026.03.10 CHANG MATTHEW WOOK

AI summary

The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.